Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel B Hawcutt

Showing results (1-10 of 103) with videos related to

Pageof 11
Sort By:
Archives of Disease in Childhood|April 10, 2015
When to report adverse drug reactions in children?Christopher Barton, Daniel B Hawcutt
Nature Reviews. Rheumatology|September 22, 2022
Paediatric glucocorticoid toxicity index: new possibilities in assessmentCharlotte King, Daniel B Hawcutt
Expert Review of Clinical Pharmacology|January 23, 2018
Solving the problem of dose optimization of children's medicinesStephen J McWilliam, Daniel B Hawcutt
Idrugs : the Investigational Drugs Journal|July 5, 2008
Drug development for children: how is pharma tackling an unmet need?Daniel B Hawcutt, Rosalind L Smyth
Archives of Disease in Childhood|March 6, 2008
One size does not fit all: getting drug doses right for childrenDaniel B Hawcutt, Rosalind L Smyth
Paediatric Drugs|May 6, 2008
The new European regulation on pediatric medicines: regulatory perspectiveDaniel B Hawcutt, Rosalind L Smyth
Seizure|October 31, 2015
Comparing paediatric intravenous phenytoin doses using physiologically based pharmacokinetic (PBPK) modelling softwareHannah Batchelor, Richard Appleton, Daniel B Hawcutt
The Lancet. Respiratory Medicine|June 2, 2018
Adrenal suppression with inhaled corticosteroids: the seed and the soil - Authors' replyDaniel B Hawcutt, Ben Francis, Munir Pirmohamed
Journal of Child Health Care : for Professionals Working with Children in the Hospital and Community|December 17, 2013
The restrictions to the use of codeine and dilemmas about safe alternativesBernie Carter, Daniel B Hawcutt, Janine Arnott
Pediatric Pulmonology|April 18, 2021
Stepping down asthma treatment in childrenCharlotte King, Eleanor Dixon, Daniel B Hawcutt
Pageof 11

Showing results (1-10 of 103) with videos related to

Sort By:
Pageof 11
Archives of Disease in Childhood|April 10, 2015
When to report adverse drug reactions in children?Christopher Barton, Daniel B Hawcutt
Nature Reviews. Rheumatology|September 22, 2022
Paediatric glucocorticoid toxicity index: new possibilities in assessmentCharlotte King, Daniel B Hawcutt
Expert Review of Clinical Pharmacology|January 23, 2018
Solving the problem of dose optimization of children's medicinesStephen J McWilliam, Daniel B Hawcutt
Idrugs : the Investigational Drugs Journal|July 5, 2008
Drug development for children: how is pharma tackling an unmet need?Daniel B Hawcutt, Rosalind L Smyth
Archives of Disease in Childhood|March 6, 2008
One size does not fit all: getting drug doses right for childrenDaniel B Hawcutt, Rosalind L Smyth
Paediatric Drugs|May 6, 2008
The new European regulation on pediatric medicines: regulatory perspectiveDaniel B Hawcutt, Rosalind L Smyth
Seizure|October 31, 2015
Comparing paediatric intravenous phenytoin doses using physiologically based pharmacokinetic (PBPK) modelling softwareHannah Batchelor, Richard Appleton, Daniel B Hawcutt
The Lancet. Respiratory Medicine|June 2, 2018
Adrenal suppression with inhaled corticosteroids: the seed and the soil - Authors' replyDaniel B Hawcutt, Ben Francis, Munir Pirmohamed
Journal of Child Health Care : for Professionals Working with Children in the Hospital and Community|December 17, 2013
The restrictions to the use of codeine and dilemmas about safe alternativesBernie Carter, Daniel B Hawcutt, Janine Arnott
Pediatric Pulmonology|April 18, 2021
Stepping down asthma treatment in childrenCharlotte King, Eleanor Dixon, Daniel B Hawcutt
Pageof 11